 Goldman Sachs Group Inc. boosted its position in shares of Aeglea Bio Therapeutics Inc NASDAQ:AGLE by 1.6 during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 442,050 shares of the biotechnology companys stock after purchasing an additional 7,051 shares during the period. Goldman Sachs ... 